Bayer starts patient enrolment in Phase III prostate cancer trial
Bayer HealthCare has started patient enrolment in a new Phase III trial of radium-223 dichloride (radium-223, Xofigo) in combination with abiraterone acetate and prednisone/prednisolone to treat asymptomatic or mildly symptomatic chemotherapy-naïve p…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Abiraterone Acetate | Cancer | Cancer & Oncology | Chemotherapy | Pharmaceuticals | Prednisolone | Prednisone | Prostate Cancer